Telix has selected Goodwin Biotechnology, Inc. to optimize the process for cGMP manufacturing of our renal cancer imaging antibody drug conjugate (TLX‐
250). The product will be used in Telix’s Phase III clinical study for the diagnostic imaging and staging of patients with clear cell renal cancer, and post‐approval commercialization.

You can read the full announcement here.